1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Post Operative Nausea And Vomiting – Pipeline Review, H1 2013

Post Operative Nausea And Vomiting – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 35 pages

Post Operative Nausea And Vomiting – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Post Operative Nausea And Vomiting - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Post Operative Nausea And Vomiting, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Operative Nausea And Vomiting. Post Operative Nausea And Vomiting - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Post Operative Nausea And Vomiting.
- A review of the Post Operative Nausea And Vomiting products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Post Operative Nausea And Vomiting pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Post Operative Nausea And Vomiting.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Post Operative Nausea And Vomiting pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Post Operative Nausea And Vomiting - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Post Operative Nausea And Vomiting Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Post Operative Nausea And Vomiting 7
Post Operative Nausea And Vomiting Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Post Operative Nausea And Vomiting Therapeutics - Products under Development by Companies 13
Companies Involved in Post Operative Nausea And Vomiting Therapeutics Development 14
GlaxoSmithKline plc 14
Axcan Pharma Inc. 15
Acacia Pharma Ltd. 16
Post Operative Nausea And Vomiting - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
rolapitant hydrochloride - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
ondansetron MR - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
vestipitant mesylate - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
droperidol - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
amisulpride - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Post Operative Nausea And Vomiting Therapeutics - Drug Profile Updates 27
Post Operative Nausea And Vomiting Therapeutics - Discontinued Products 30
Post Operative Nausea And Vomiting Therapeutics - Dormant Products 31
Post Operative Nausea And Vomiting - Product Development Milestones 32
Featured News and Press Releases 32
May 28, 2012: Acacia Pharma Announces Positive Results For APD421 In Post-Operative Nausea and Vomiting 32
Jul 09, 2008: Aloxi (Palonosetron Hcl) Injection Available For Prevention Of Postoperative Nausea And Vomiting 32
Mar 03, 2008: FDA Approves Aloxi (Palonosetron Hcl) Injection For Prevention Of Postoperative Nausea And Vomiting 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35



List of Tables

Number of Products Under Development for Post Operative Nausea And Vomiting, H1 2013 7
Products under Development for Post Operative Nausea And Vomiting - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
GlaxoSmithKline plc, H1 2013 14
Axcan Pharma Inc., H1 2013 15
Acacia Pharma Ltd., H1 2013 16
Assessment by Monotherapy Products, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 21
Post Operative Nausea And Vomiting Therapeutics - Drug Profile Updates 27
Post Operative Nausea And Vomiting Therapeutics - Discontinued Products 30
Post Operative Nausea And Vomiting Therapeutics - Dormant Products 31



List of Figures

Number of Products under Development for Post Operative Nausea And Vomiting, H1 2013 7
Products under Development for Post Operative Nausea And Vomiting - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 17
Assessment by Route of Administration, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 19
Assessment by Molecule Type, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.